Want to see ORIC full AI Analyst Report?

Oric Pharmaceuticals (ORIC) Price & Analysis

523 Followers

ORIC Stock Chart & Stats

$10.75

-$0.67(-7.21%)

At close: Jan 08 4:00 PM EST

$10.75

-$0.67(-7.21%)

Day’s Range― - ―

52-Week Range$7.23 - $14.93

Previous CloseN/A

Volume181.02K

Average Volume (3M)1.85M

Market Cap

$1.13B

Enterprise Value$840.26M

Total Cash (Recent Filing)$281.93M

Total Debt (Recent Filing)$3.30M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Aug 06, 2026

EPS Estimate

-0.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.44

Shares Outstanding103,517,560

10 Day Avg. Volume1,749,924

30 Day Avg. Volume1,846,865

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.87

Price to Sales (P/S)0.00

P/FCF Ratio-6.30

Enterprise Value/Market Cap0.74

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.63K

Enterprise Value/Ebitda-6.27

Forecast

1Y Price Target

$19.67

Price Target Upside82.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.46

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Sizable Equity BaseThe balance sheet shows zero reported debt and roughly $415.6M of equity. Low leverage materially reduces default and interest‑rate exposure and gives the company structural flexibility to fund R&D or pursue partnerships, supporting program continuity absent extreme cash shocks.

Governance Changes Tighten Compensation OversightShareholder approval of an amended equity incentive plan, caps on option issuance and removal of repricing, plus board elections and auditor ratification, create lasting compensation discipline and stronger oversight. This reduces governance risk and supports more predictable capital allocation and investor confidence.

Focused Oncology Pipeline Addressing ResistanceOric’s strategy centers on a differentiated oncology program targeting resistance mechanisms—a structural unmet-need area. If clinical progression continues, this focused approach can yield durable competitive advantages, attract partnerships or licensing, and create high-value assets over the medium term.

Bears Say

No Product RevenueThe company has no product-derived revenue, consistent with a clinical-stage profile. This structural absence of a revenue base forces ongoing reliance on external financing and partner deals to sustain operations, leaving profitability and self-funding distant over the next several quarters.

Accelerating Cash Burn And Negative Free Cash FlowTrailing-12-month operating cash flow (~-$110.9M) and free cash flow (~-$111.4M) with roughly -64% FCF deterioration signal accelerating burn. This persistent negative cash generation shortens runway, increases odds of near-term financings, and constrains the firm's ability to fund multiple programs simultaneously.

Reliance On Equity Financing / Dilution RiskWith no product cash flows and widening losses, the company structurally depends on equity raises to fund operations. Continued capital raises are likely while burn persists, increasing dilution risk and potentially limiting shareholder returns and management flexibility over the coming 2–6 months.

Oric Pharmaceuticals News

Oric Pharmaceuticals resumed with a Buy at Stifel

Stifel analyst Laura Prendergast resumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $14 price target...

28d ago

ORIC

Oric Shareholders Approve Equity Plan, Governance Measures

Oric Pharmaceuticals ( ($ORIC) ) just unveiled an announcement. On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an...

17d ago

ORIC

Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained

Oric Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from...

1M ago

ORIC

ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst

Goldman Sachs analyst Corinne Johnson has maintained their bullish stance on ORIC stock, giving a Buy rating on...

2M ago

ORIC

Oric Pharmaceuticals moved to Buy rating at Goldman Sachs

Goldman Sachs moved Oric Pharmaceuticals (ORIC) to a Buy rating and $15 price target from its Early Stage...

2M ago

ORIC

ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts

In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a...

2M ago

ORIC

Oric Pharmaceuticals price target lowered to $16 from $17 at Citi

Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy...

2M ago

ORIC

Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)

“The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat,...

2M ago

ORIC

Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research...

3M ago

ORIC

3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts

Which stocks are best to buy now amid the recent market pullback? According to Top Wall Street Analysts,...

3M ago

ENGN

ORIC

Oric selloff brings attractive entry point, says H.C. Wainwright

H.C. Wainwright analyst Robert Burns says the pullback this week in shares of Oric Pharmaceuticals (ORIC) provides an...

3M ago

ORIC

Oric Pharmaceuticals should be bought on selloff, says Citi

Citi recommends using today’s weakness in shares of Oric Pharmaceuticals (ORIC) as a buying opportunity. The 30% pullback...

3M ago

ORIC

Midday Fly By: Nike falls after earnings, Conagra reports mixed results

The major averages were broadly higher near noon, building on yesterday’s strong session. Markets are staging a sharp...

3M ago

Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush

Wedbush analyst David Nierengarten lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $17 from $20 and...

3M ago

PFE

ORIC

ORIC FAQ

What was Oric Pharmaceuticals Inc’s price range in the past 12 months?

Oric Pharmaceuticals Inc lowest stock price was $7.23 and its highest was $14.93 in the past 12 months.

What is Oric Pharmaceuticals Inc’s market cap?

Oric Pharmaceuticals Inc’s market cap is $1.13B.

When is Oric Pharmaceuticals Inc’s upcoming earnings report date?

Oric Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.

How were Oric Pharmaceuticals Inc’s earnings last quarter?

Oric Pharmaceuticals Inc released its earnings results on May 04, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.019.

Is Oric Pharmaceuticals Inc overvalued?

According to Wall Street analysts Oric Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals Inc pay dividends?

Oric Pharmaceuticals Inc does not currently pay dividends.

What is Oric Pharmaceuticals Inc’s EPS estimate?

Oric Pharmaceuticals Inc’s EPS estimate is -0.36.

How many shares outstanding does Oric Pharmaceuticals Inc have?

Oric Pharmaceuticals Inc has 103,517,560 shares outstanding.

What happened to Oric Pharmaceuticals Inc’s price movement after its last earnings report?

Oric Pharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went down -0.623%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ORIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oric Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-35.33%

Trailing 12-Months

Asset Growth

79.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Oric Pharmaceuticals (ORIC) Earnings & Revenues

Historic Earnings Reports

ORIC Stock 12 Month Forecast

Average Price Target

$19.67

▲(82.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","11":"$11","16":"$16","21":"$21","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.666666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,11,16,21,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.89,11.975384615384616,13.060769230769232,14.146153846153847,15.231538461538463,16.31692307692308,17.402307692307694,18.487692307692306,19.573076923076925,20.658461538461538,21.743846153846157,22.82923076923077,23.914615384615384,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.89,11.565128205128206,12.24025641025641,12.915384615384616,13.59051282051282,14.265641025641026,14.94076923076923,15.615897435897438,16.29102564102564,16.966153846153848,17.64128205128205,18.316410256410258,18.99153846153846,{"y":19.666666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.89,11.12923076923077,11.368461538461538,11.607692307692307,11.846923076923078,12.086153846153847,12.325384615384616,12.564615384615385,12.803846153846154,13.043076923076924,13.282307692307693,13.521538461538462,13.760769230769231,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.88,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.475,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >